

# Contents

<b>1</b>	<b>Beta-Blockers: <i>The Cornerstone of Cardiac Drug Therapy</i>.....</b>	<b>1</b>
	This chapter tells you .....	1
	Beta-Blockers and Cardioprotection .....	2
	Beta-Receptors .....	6
	Mechanism of Action .....	9
	Other Important Clinically Beneficial Mechanisms .....	10
	Beta-Blocker Effect on Calcium Availability.....	10
	Dosage Considerations .....	11
	Pharmacologic Properties and Clinical Implications .....	14
	Cardioselectivity.....	14
	Intrinsic Sympathomimetic Activity .....	18
	Membrane-Stabilizing Activity .....	19
	Effects on Renin .....	19
	Lipid Solubility.....	20
	Plasma Volume .....	20
	Hepatic Metabolism .....	21
	Effects on Blood and Arteries .....	21
	Effect on Serum Potassium.....	22
	Salutary Effects of Beta-Adrenergic Blockade .....	23

Beta-Blockers Versus Calcium Antagonists and Oral Nitrates.....	24
Indications for Beta-Blockers .....	26
Angina .....	26
Arrhythmias.....	26
Acute Myocardial Infarction.....	29
Elective Percutaneous Coronary Intervention (PCI) .....	29
Heart Failure .....	31
Prolonged QT Interval Syndromes .....	33
Dissecting Aneurysm.....	33
Mitral Valve Prolapse .....	34
Mitral Regurgitation and Mitral Stenosis...	34
Tetralogy of Fallot.....	34
Hypertrophic Cardiomyopathy .....	34
Marfan's Syndrome .....	35
Subarachnoid Hemorrhage.....	36
Perioperative Mortality.....	36
Neurocardiogenic Syncope (Vasovagal/ Vasodepressor Syncope) .....	38
Diabetic Patients.....	39
Chronic Obstructive Pulmonary Disease ...	39
Noncardiac Indications .....	41
Advice and Adverse Effects.....	41
Warnings.....	41
Side Effects.....	43
Individual Beta-Blockers.....	44
Dosage (Further Advice).....	47
Action.....	48
Indications.....	48
Dosage (Further Advice).....	49
Action.....	50
Indications.....	50
Dosage (Further Advice).....	52
Indications.....	56
Indications.....	57
Contraindications.....	58

Which Beta-Blocker Is Best for Your Patients? .....	58
References .....	61
<b>2 Beta-Blocker Controversies .....</b>	<b>69</b>
Beta-Blockers Are not a Good Initial Choice for Hypertension: True or False? .....	69
Beta-Blockers Are not Recommended for Treatment of Elderly Hypertensives: True or False? .....	73
Beta-Blockers Cause Genuine Diabetes Mellitus: True or False? .....	74
Do all Beta-Blockers Cause Benign Glucose Intolerance? .....	78
Beta-Blockers Should not Be Given to Patients During the Early Hours of Acute Mi: True or False? .....	79
References .....	80
<b>3 Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers .....</b>	<b>85</b>
Mechanism of Action .....	86
ACE Inhibitors Versus Other Vasodilators ....	93
Clinical Indications .....	94
Hypertension .....	94
Heart Failure .....	97
Acute Myocardial Infarction .....	100
Renoprotection .....	101
Coarctation of the Aorta .....	104
Pulmonary Hypertension .....	105
Scleroderma Renal Crisis .....	105
Bartter's Syndrome .....	105
ACE Inhibitors/ARBs and Diabetes .....	105
Contraindications .....	106
Advice, Adverse Effects, and Interactions ....	107
Hypotension .....	107
Renal Failure .....	107

Hyperkalemia .....	107
Cough .....	107
Loss of Taste Sensation .....	108
Angioedema .....	108
Rash .....	109
Proteinuria .....	109
Neutropenia and Agranulocytosis .....	109
Mild Dyspnea and/or Wheeze .....	109
Anaphylactoid Reactions.....	109
Uncommon Adverse Effects .....	110
Interactions.....	110
Individual ACE Inhibitors.....	110
Pharmacologic Profile and Individual	
Differences.....	110
Subtle Differences .....	110
Hypotension .....	111
Dosage (Further Advice).....	112
Pharmacokinetics.....	112
Dosage (Further Advice).....	113
Pharmacokinetics.....	114
Dosage (Further Advice).....	115
Pharmacokinetics.....	115
Dosage (Further Advice).....	116
Angiotensin II Receptor Blockers .....	119
Clinical Trials .....	120
References .....	124
<b>4 ACE Inhibitor ARB Controversies.....</b>	<b>129</b>
ACE Inhibitors Versus ARBs:	
Does the Choice Matter? .....	129
ACE Inhibitors/ARBs Cause	
Renoprotection: True or False?.....	132
ACE Inhibitors Decrease the Incidence	
of Diabetes: True or False? .....	134
Combination of ACE Inhibitor and ARB	
Proven Effective: True or False?.....	135
References .....	136

<b>5 Calcium Antagonists (Calcium Channel Blockers)</b>	139
Mechanism of Action	140
Action	143
Adverse Effects and Interactions for DHPs	144
Action	147
Adverse Effects and Interactions	147
Action	149
Advice, Adverse Effects, and Interactions	150
Dosage (Further Advice)	153
Indications for Calcium Antagonists	153
Hypertension	153
Stable Angina	154
References	158
<b>6 Calcium Antagonist Controversies</b>	161
Calcium Antagonists Cause an Increased Incidence of HF and MI: True or False?	161
Newer Calcium Antagonists Are Better Than Older Agents: True or False?	162
Are Calcium Antagonists Safe for Hypertensives with CAD?	163
INVEST	163
CONVINCE	164
References	166
<b>7 Diuretics</b>	167
Indications	170
Hypertension	170
Heart Failure	171
Thiazides	172
Loop Diuretics	174
Mechanism of Action	174
Dosage (Further Advice)	175
Action and Pharmacokinetics	175
Potassium-Sparing Diuretics	179

Advantages .....	182
Disadvantages.....	183
Combination of a Thiazide or Furosemide and Potassium-Sparing Diuretic .....	185
Other Diuretics .....	186
Potassium Chloride Supplements.....	187
Potassium Chloride.....	190
Salt Substitutes.....	190
Further Advice.....	192
Torsemide.....	192
Aldosterone Antagonists .....	192
References .....	195
<b>8 Hypertension.....</b>	<b>199</b>
Relevant Key Issues .....	199
Controversies .....	205
Definitions .....	206
Isolated Systolic Hypertension in Older Patients .....	206
Pseudohypertension.....	207
Home Measurements .....	208
Nondrug Therapy.....	208
Which Drugs to Choose.....	209
Recommendations for Patients Without Coexisting Disease .....	210
Therapy for Patients with Coexisting Diseases.....	220
Beta-Blockers.....	223
Dosage.....	223
Action of Beta-Blockers .....	224
Diuretics.....	227
Action.....	227
Use Proven in Elderly .....	229
Chlorthalidone .....	231
ACE Inhibitors and Angiotensin II Receptor Blockers.....	234

Adverse Effects and Interactions .....	236
Contraindications.....	237
Dosage (Further Advice).....	238
ACE Inhibitor-Diuretic Combination.....	239
Calcium Antagonists .....	240
Alpha1-Blockers .....	243
Centrally Acting Drugs.....	244
Resistant Hypertension .....	244
Catheter-Based Radiofrequency Renal Denervation.....	246
Hypertensive Crisis .....	247
Action and Metabolism.....	250
Advice, Adverse Effects, and Interactions ....	250
References .....	253
<b>9 Hypertension Controversies.....</b>	<b>261</b>
Beta-Blockers Should Not Remain First Choice in the Treatment of Primary Hypertension: True or False? .....	261
Conclusion .....	268
Diabetic Risk with Beta-Blockers and Diuretics .....	269
An Increased Risk: True or False? .....	269
Hypertensive Agents Increase Heart Failure Risk: True or False? .....	271
Age and Ethnicity Hold the Key for Drug Choice .....	272
References .....	278
<b>10 Angina.....</b>	<b>283</b>
Salient Clinical Features .....	283
Pathophysiologic Implications .....	284
Treatment of Stable Angina .....	285
Beta-Adrenoceptor Blocking Agents.....	286
Cardioprotection and Dosage of Beta-Blocker .....	290
Contraindications to Beta-Blockers .....	290

Combination of Beta-Blockers and Calcium Antagonists .....	292
Nitrates .....	292
Cutaneous Nitroglycerins .....	293
Cutaneous Nitrates .....	295
Indications.....	298
Aspirin.....	299
Ranolazine .....	301
Consider Interventional Therapy .....	303
Management of Unstable Angina .....	303
Investigations.....	303
Medications.....	304
Statins.....	306
Variant Angina (Prinzmetal's) .....	306
References .....	307
<b>11 Myocardial Infarction .....</b>	<b>311</b>
Overview.....	311
TRIGGERS for ACS .....	313
DIAGNOSIS.....	314
Electrocardiographic Features.....	317
Inferior MI Diagnosis.....	317
Anterior MI Diagnosis.....	317
ECG Mimics of Acute Myocardial Infarction.....	320
Therapy .....	330
Pain Relief .....	332
Percutaneous Coronary Intervention .....	334
Clopidogrel .....	335
Prasugrel .....	335
Ticagrelor (BRILINTA; Brilique in UK) .....	336
Thrombolytic Therapy.....	339
The incidence of ICH in RCTs was reported as follows .....	341
Contraindications.....	341



Streptokinase [Kabikinase, Streptase].....	342
Tenecteplase .....	343
Enoxaparin .....	343
Fondaparinux .....	344
Beta-Blockers.....	345
ACE Inhibitors .....	348
NITRATES .....	349
STATINS .....	350
Management of Complications of Infarction.....	350
Arrhythmias.....	350
Heart Failure .....	353
Right Ventricular Infarction .....	354
Cardiogenic Shock .....	354
Management.....	355
Early Reperfusion.....	356
Management of Non-ST-Elevation Myocardial Infarction .....	357
Conservative Generally Preferred [angiogram 24–36 h] .....	360
Medications on Discharge .....	360
References .....	361
<b>12 Heart Failure .....</b>	<b>369</b>
The Size of the Problem .....	369
Causes of Heart Failure .....	372
Basic Cause.....	372
Diagnosis .....	376
Pathophysiology.....	379
Management Guide .....	381
Vasodilators .....	382
ACE Inhibitors/Angiotensin II Receptor Blockers .....	382
Angiotensin-Receptor Blockers.....	387
Transcend (2008).....	388

Hydralazine .....	389
Calcium Antagonists .....	389
Amlodipine .....	389
Diuretics.....	389
Indications and Guidelines .....	389
Aldosterone Antagonists .....	390
Beta-Blockers.....	393
Inotropic Agents .....	399
Digoxin Studies .....	399
Dosage Considerations .....	405
Symptoms of Toxicity .....	409
Beta-Stimulants .....	412
New Developments .....	413
Spironolactone .....	413
Istaroxime .....	413
Omecamtiv mecarbil .....	414
SERCA2a.....	413
Serelaxin.....	414
Rosuvastatin .....	415
LCZ696 .....	415
Management of Pulmonary Edema .....	415
References .....	417
<b>13 Heart Failure Controversies.....</b>	<b>423</b>
Are ARBs as Effective as ACE Inhibitor Therapy for Heart Failure? .....	423
Management of Heart Failure Preserved Ejection Fraction .....	424
Treatment.....	426
Digoxin Is Not Useful for HFPEF: True or False?.....	427
Is CHARM-Preserved a Clear Study of HFPEF?.....	427
Does an ACE Inhibitor Combined with an ARB Improve Outcomes?.....	428
Heart Failure in Blacks: Do Differences Exist?.....	429

Are Statins Recommended for Patients with Heart Failure? .....	429
References .....	430
<b>14 Arrhythmias .....</b>	<b>433</b>
Classification .....	434
Diagnosis of Arrhythmias.....	435
Arrhythmias with Narrow QRS Complex .....	437
Arrhythmias with Wide QRS Complex .....	437
Management of Supraventricular Arrhythmias .....	454
AV Nodal Reentrant Tachycardia .....	454
Multifocal Atrial Tachycardia (Chaotic Atrial Tachycardia) .....	459
Paroxysmal Atrial Tachycardia with Block .....	459
Atrial Premature Contractions .....	460
Atrial Flutter .....	460
Atrial Fibrillation.....	462
Chronic Atrial Fibrillation.....	465
Atrial Fibrillation Post Surgery.....	466
Synchronized DC Cardioversion .....	466
Rate Control Versus Rhythm Control .....	467
Anticoagulants for AF .....	469
Newer Anticoagulants.....	470
Genetically Mediated Arrhythmic Disorders .....	472
Wolff–Parkinson–White Syndrome .....	472
Ventricular Arrhythmias.....	477
Premature Ventricular Contractions: Benign Arrhythmias .....	477
Ventricular Tachycardia .....	478
Fatal Ventricular Arrhythmias.....	478
Antiarrhythmic Agents .....	481

Class IA.....	481
Advice, Adverse Effects, and Interactions .....	483
Class IB .....	486
Class IC .....	488
Class II.....	490
Class III.....	492
Adverse Effects.....	494
References .....	496
<b>15 Cardiac Arrest.....</b>	<b>503</b>
“Time Is of the Essence” .....	503
Two Cardiac Rhythms.....	505
Basic Life Support.....	507
Defibrillation .....	510
Drug Therapy .....	512
Asystole and Pulseless Idioventricular Rhythms .....	514
Isoproterenol Is Contraindicated in the Treatment of Cardiac Arrest .....	514
Beta-Blockers.....	514
References .....	514
<b>16 Infective Endocarditis.....</b>	<b>517</b>
Classification and Diagnosis .....	518
Diagnostic Guidelines .....	518
Therapy .....	522
<i>S. aureus</i> Endocarditis .....	523
Prosthetic Valve Endocarditis .....	525
Native Valve Endocarditis Caused by Staphylococci.....	525
Native Valve Endocarditis .....	525
Prosthetic Valve Endocarditis Caused by Susceptible <i>S. viridans</i> or <i>S. bovis</i> Infections.....	526
Other Bacteria Causing IE .....	528
Right-Sided Endocarditis.....	528
Fungal Endocarditis.....	530

Heart Failure Complicating Endocarditis.....	532
Prophylaxis of Bacterial Endocarditis .....	533
Older Regimen Acceptable to Many .....	535
References .....	538
<b>17 Dyslipidemias.....</b>	<b>541</b>
Diagnosis .....	541
Fasting or Non-fasting LDL-C? .....	541
Conversion Formula for mg to mmol.....	543
Secondary Causes of Dyslipidemias.....	543
Dietary Therapy.....	545
Drug Therapy .....	547
Statins.....	549
Statins Possess Subtle Differences.....	550
Advice and Adverse Effects .....	550
Nicotinic Acid .....	561
Adverse Effects and Interactions .....	562
Fibrates .....	563
HDL Lowering .....	565
Evacetrapib.....	565
References .....	566
<b>18 Endocrine Heart Diseases.....</b>	<b>571</b>
Acromegaly .....	571
Management .....	571
Carcinoid Syndrome.....	572
Cushing's Syndrome.....	573
Diabetes and the Heart .....	573
Which Cardiovascular Drugs Are Best	
ACE Inhibitors/ARBs? .....	574
Beta-Blockers Underused in Diabetics.....	574
Aspirin.....	575
Dyslipidemia in Diabetics.....	575
Blood Pressure Control.....	576
Oral Diabetic Agents .....	577
Metformin .....	577
Sulfonylurea.....	578

Thiazolidinediones .....	579
Acarbose (Glucobay) .....	579
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Gliptins).....	580
Hyperaldosteronism .....	581
Pheochromocytoma.....	581
Hyperthyroidism.....	586
Cardiac Disturbances .....	586
Hypothyroidism .....	588
Cardiac Involvement .....	588
References .....	588
<b>19 Antiplatelet Agents, Anticoagulants, Factor Xa Inhibitors, and Thrombin Inhibitors .....</b>	<b>593</b>
Antiplatelet Agents .....	593
Historical Review.....	597
Actions .....	599
Aspirin Resistance .....	601
Indications.....	602
Platelet Glycoprotein IIb/IIIa Receptor Blockers .....	608
Anticoagulants .....	610
Low-Molecular-Weight Heparin .....	612
Specific Thrombin Inhibitors.....	613
Factor Xa Inhibitors .....	615
References .....	618
<b>20 Cardiac Drugs During Pregnancy and Lactation .....</b>	<b>623</b>
Antihypertensive Agents in Pregnancy .....	623
Methyldopa.....	625
Calcium Antagonists.....	631
ACE Inhibitors.....	632
Magnesium Sulfate .....	632
Aspirin.....	633
Drug Therapy for Heart Failure .....	634
Diuretics .....	636

Antiarrhythmics in Pregnancy .....	636
Adenosine .....	636
Beta-Adrenergic Blockers .....	637
Disopyramide .....	637
Lidocaine.....	637
Cardiac Drugs During Lactation .....	638
References .....	642
<b>21 Drug Interactions .....</b>	<b>645</b>
Interactions of Cardiovascular Drugs.....	646
ACE Inhibitors/ARBs.....	646
Antiarrhythmic Agents .....	649
Adenosine .....	649
Amiodarone.....	649
Disopyramide .....	651
Flecainide .....	651
Lidocaine or Lignocaine .....	651
Mexiletine .....	652
Phenytoin .....	652
Propafenone .....	652
Procainamide .....	652
Quinidine .....	653
Antiplatelet Agents/Anticoagulants .....	653
Beta-Blockers.....	654
Calcium Antagonists .....	655
Digoxin.....	658
Diuretics.....	658
Nitrates.....	659
Lipid-Lowering Agents.....	660
Statins .....	660
Interactions of Cardiac and Noncardiac Drugs.....	660
Antibiotics.....	660
Antimalarials .....	663
Anticonvulsants.....	663
Cyclosporine .....	663
Lithium .....	664

Nonsteroidal Anti-inflammatory Drugs.....	664
Psychotropic Agents .....	664
Theophylline .....	665
Thyroxine .....	665
Cardiac Effects of Noncardiac Drugs .....	667
Antibiotics.....	667
Antimalarials .....	667
Histamine H <sub>1</sub> Antagonists.....	667
Antidepressants.....	669
Cancer Chemotherapeutic Agents.....	670
Other Agents .....	670
References .....	673
<b>22 Hallmark Clinical Trials.....</b>	<b>675</b>
Acute Coronary Syndrome RCTs.....	676
ATLAS ACS 2–TIMI 51: Rivaroxaban for ACS.....	676
Bivalirudin for ACS.....	677
LMWH and Major Bleeding Advice.....	681
IV Metoprolol Studies .....	689
COMMIT/CCS-2: Second Chinese Cardiac Study (CCS-2) (31) .....	690
The METOCARD-CNIC .....	691
Aspirin for Cardiovascular Disease Prevention .....	692
Aspirin Pseudoresistance .....	692
Angina RCTs .....	692
PCI Versus Optimal Medical Therapy .....	692
Carvedilol in Postinfarct Patients .....	694
Atrial Fibrillation RCTs .....	694
Lenient Rate Control .....	694
Rate Versus Rhythm Control in Atrial Fibrillation.....	695
Newer Anticoagulants for Reduction in Stroke .....	696
RE-LY 2010: Dabigatran Versus Warfarin in Patients with Atrial Fibrillation.....	696



Colchicine for Cardiovascular Disease .....	698
Colchicine for Stable Coronary	
Artery Disease .....	698
Colchicine for pericarditis.....	699
Colchicine for Post-op Atrial	
Fibrillation .....	699
Heart Failure RCTs.....	701
COPERNICUS 2001: Carvedilol	
in Severe Chronic HF .....	701
Heart Failure Trials.....	702
MERIT-HF 2000: Metoprolol CR/XL	
in Chronic Heart Failure .....	702
The Seniors Study: Nebivolol	
for Heart Failure .....	702
Aldosterone Antagonist Trials .....	703
ACE Inhibitors and ARB RCTs .....	704
PROFESS 2008: Telmisartan	
to Prevent Recurrent Stroke .....	707
Hypertension Trials .....	709
ALLHAT 2002 .....	709
Nebivolol Combined with	
Valsartan Study .....	710
Dyslipidemia RCTs .....	712
Early and Late Benefits of High-Dose	
Atorvastatin .....	712
Arrhythmia RCTs.....	718
AFFIRM (2002): Rate Versus Rhythm	
Control in Atrial Fibrillation .....	718
Beta-Blockers And Diabetes .....	718
GEMINI (2004): Beta-Blockers	
for Hypertensive Diabetics.....	718
Clonidogrel.....	719
PCI-Clarity: Clopidogrel Before PCI.....	719
Folic Acid/B6, B12.....	720
HOPE-2: Homocysteine Lowering.....	720
References .....	721

<b>23</b>	<b>Management of Cardiomyopathies .....</b>	<b>729</b>
	Hypertrophic Cardiomyopathy.....	729
	Pathophysiology .....	730
	Clinical Diagnosis .....	731
	Therapy .....	735
	Implantable Cardioverter-Defibrillators.....	738
	Risk Factors for Sudden Death and Guide for ICD Include .....	738
	Dilated Cardiomyopathy .....	739
	Diagnosis.....	739
	Physical Signs .....	740
	Echocardiogram .....	741
	Therapy .....	741
	Restrictive Cardiomyopathy .....	744
	Clinical Features.....	745
	Therapy .....	748
	Peripartum Cardiomyopathy .....	748
	Treatment .....	749
	References .....	750
<b>24</b>	<b>Newer Agents.....</b>	<b>755</b>
	Apixaban .....	755
	Rivaroxaban .....	757
	Dabigatran.....	758
	Edoxaban .....	760
	Conclusion .....	760
	Omecamtiv Mecarbila.....	761
	Celivarone .....	761
	Dronedarone .....	762
	Nebivolol .....	763
	Prasugrel [Efient IN UK] .....	763
	Ticagrelor [Brilinta; Brilique in UK].....	764
	Cangrelor .....	765
	Evacetrapib .....	765
	References .....	766
	<b>Index.....</b>	<b>769</b>

Cardiac Drug Therapy

Khan, M.G.

2015, XXXII, 791 p. 44 illus., 6 illus. in color., Softcover

ISBN: 978-1-61779-961-7

A product of Humana Press